vialroom

#retatrutide 2026-05-22

Friday36 messages9 participantstimes are UTC
Highlights from this day
  • reta_resting_hr — GI was about the same as tirzepatide for me, the difference was how fast it arrived 22:17
  • egfr_ed — i said 3 months ago that my heart rate had settled and it has stayed settled since 22:28
  • deadspace — is the glucagon arm what people mean by the energy expenditure thing 22:57
VB

Testing queue: 2 submissions open, 38 awaiting dispatch.

SS

stopped for 6 months and restarted at half my old dose, the ramp was easier second time

TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

BB

blood pressure stayed flat for me while heart rate moved, which i didnt expect

[edited]

settled by month three

SS

sorry to jump in i log resting heart rate every morning because of this and its the one number i actually watch, not advice obviously

NP

lost 48kg over 20 months at doses well under what the trials used

no long term data

energy expenditure isnt something i could feel, though my sleep tracker disagreed with me, take that with a pinch of salt

SS

why does everyone insist on smaller steps here than on the other two

update on the earlier thing low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

JJ

coming back to this anyone reconstituting 40 vials to 10 so the steps come out smaller

RR

quick one appetite suppression at 15 was stronger than my tirzepatide experience at a comparable point

🤝3⚠️1🔥2
JJ

my resting rate went up 8 bpm in the first month and came back most of the way by month 3

right so i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps

📉1
EE

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

is the phase 2 dosing anywhere near what people here run

does the energy expenditure claim show up as anything you can feel

whats a sensible starting point, im seeing everything from 0.5 to 2

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

GI was about the same as tirzepatide for me, the difference was how fast it arrived

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
EE

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me, still working it out

🔥2🙏2
EE

i said 3 months ago that my heart rate had settled and it has stayed settled since

❤️116
EE

Janoshik came back 98.6 on one lot and 99.2 on the next from the same GL Biochem, both fine

logging rhr daily

no idea whether the heart rate settles for everyone, mine did and one log isnt data

DE

is the glucagon arm what people mean by the energy expenditure thing

[edited]
7❤️7🧪8
EE

the half life supports weekly dosing and thats what ive done from the start

JJ

came off at 20 weeks because my resting rate stayed elevated and i didnt like it, for what its worth